



Follow-up programme for children and teenagers with early-stage Type 1 Diabetes

-Tier 3-



www.edent1fi.eu

EDENT1FI 
European action for the Diagnosis of Early
Non-clinical Type 1 diabetes For disease Interception

Dear Parents,

Based on the information gathered during the baseline visit, we estimated that your child has a high risk to develop symptomatic Stage 3 T1D within the next 2 years. This means that for every 2 kids in the ‘high risk’ group, 1 will enter Stage 3 in the 2 years following the baseline visit, while the other will enter Stage 3 at a later point.

Our aim is to monitor and handle the progression of T1D in the best possible way. This is why we propose you a tailored follow-up programme, as shown in the scheme on page 3. A team of professionals will guide you in this journey to ensure you and your family feel supported and prepared for the symptoms of T1D. The follow-up programme ends when your child needs insulin treatment, but you are free to withdraw at any point!

What to do between follow-up visits?

At this stage there is no need to adapt your lifestyle. What you can do is to monitor the following signs:

- fatigue and lack of energy
- weight loss
- frequent urination
- thirst
- signs of dehydration (like dry skin)

You can also use the glucose meter you received at the first visit any time your child experiences illness or you suspect symptoms. You can also keep track of the blood glucose changes recorded by the CGM sensor. If you are in doubt about the glucose measurements, do not hesitate to contact your reference doctor, he/she is there to help you!

Notes:

Performed at every
Follow-up visit



Venous blood sample:

- Autoantibodies
- Haemoglobin A1c
- Blood cells
- Inflammation
- Viral infection



CGM sensor

Performed only at
certain visits




Home glucose meter



Questionnaires




Oral Glucose
Tolerance Test



The parameters you can monitor are:

Glucose meter



CGM sensor





EDENT1FI

European action for the Diagnosis of Early
Non-clinical Type 1 diabetes For disease Interception



This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101132379. The JU receives support from the European Union's Horizon Europe research and innovation programme, from The Leona M. and Harry B. Helmsley Charitable Trust, from Breakthrough T1D, from EFPIA, from COCIR, from Vaccines Europe, from EuropaBio and from MedTech. Additional funding is provided to associated UK partners through the UKRI (UK Research and Innovation) Guarantee Fund.